Prognostic Factors for Survival in ICI-Treated NSCLC: An Umbrella Review of Evidence Certainty and Clinical Relevance

Abstract Purpose Immune checkpoint inhibitors (ICIs) have reshaped the treatment of non-small cell lung cancer (NSCLC), yet the prognostic value of many reported factors remains uncertain. We conducted an umbrella review to evaluate the strength and credibility of evidence linking prognostic factors to overall survival in ICI-treated NSCLC. Methods PubMed, Embase, Web of Science, and the Cochrane Library were searched through July 1, 2026. Overlapping meta-analyses were managed using prespecified criteria. Pooled hazard ratios were recalculated, and heterogeneity, prediction intervals, small-study effects, excess significance, and a 10% credibility ceiling were assessed. Evidence was graded using an adapted Ioannidis framework, and methodological quality was evaluated with AMSTAR 2. Results Seventy-six meta-analyses yielded 113 associations across eight prognostic domains, of which 112 were gradable. Seven associations achieved Class I evidence: pretreatment Advanced Lung Cancer Inflammation Index, tissue tumor mutational burden, probiotic exposure, two pretreatment imaging/artificial intelligence-based risk models, ICI-associated thyroid dysfunction, and setting-specific cutaneous immune-related adverse events. Seventeen associations were Class II, 16 Class III, 31 Class IV, and 41 Class V. Several post-baseline and medication-related associations remained susceptible to time-dependent bias and residual confounding. Only 34 reviews were rated as high or moderate quality by AMSTAR 2. Conclusions Only a small proportion of proposed prognostic factors were supported by highly credible evidence. Statistical credibility does not establish causality, predictive utility, or clinical applicability. Prospective validation using standardized definitions, appropriate time-dependent analyses, and external validation of prognostic models is warranted.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-11-14
DOI
https://doi.org/10.1093/oncolo/oyag453
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prognostic Factors for Survival in ICI-Treated NSCLC: An Umbrella Review of Evidence Certainty and Clinical Relevance

Kaibo Guo, Jiamin Lu, Kai Zhang, Yuqian Feng
The Oncologist
Cancer Immunotherapy and Biomarkers
article

Prognostic Factors for Survival in ICI-Treated NSCLC: An Umbrella Review of Evidence Certainty and Clinical Relevance

Kaibo Guo, Jiamin Lu, Kai Zhang, Yuqian Feng
article en

Abstract

Abstract Purpose Immune checkpoint inhibitors (ICIs) have reshaped the treatment of non-small cell lung cancer (NSCLC), yet the prognostic value of many reported factors remains uncertain. We conducted an umbrella review to evaluate the strength and credibility of evidence linking prognostic factors to overall survival in ICI-treated NSCLC. Methods PubMed, Embase, Web of Science, and the Cochrane Library were searched through July 1, 2026. Overlapping meta-analyses were managed using prespecified criteria. Pooled hazard ratios were recalculated, and heterogeneity, prediction intervals, small-study effects, excess significance, and a 10% credibility ceiling were assessed. Evidence was graded using an adapted Ioannidis framework, and methodological quality was evaluated with AMSTAR 2. Results Seventy-six meta-analyses yielded 113 associations across eight prognostic domains, of which 112 were gradable. Seven associations achieved Class I evidence: pretreatment Advanced Lung Cancer Inflammation Index, tissue tumor mutational burden, probiotic exposure, two pretreatment imaging/artificial intelligence-based risk models, ICI-associated thyroid dysfunction, and setting-specific cutaneous immune-related adverse events. Seventeen associations were Class II, 16 Class III, 31 Class IV, and 41 Class V. Several post-baseline and medication-related associations remained susceptible to time-dependent bias and residual confounding. Only 34 reviews were rated as high or moderate quality by AMSTAR 2. Conclusions Only a small proportion of proposed prognostic factors were supported by highly credible evidence. Statistical credibility does not establish causality, predictive utility, or clinical applicability. Prospective validation using standardized definitions, appropriate time-dependent analyses, and external validation of prognostic models is warranted.

The Oncologist
Zhejiang Chinese Medical University (CN), Zhejiang Provincial Hospital of TCM (CN), Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon